All In Biotech

Drug Trial Radar · NCT00433459

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents

Last checked: Nov 20, 2026Latest source record: Mar 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,134

Actual

Start

Jan 2007

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
Christine Mauz-KörholzAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.

Conditions

  • Lymphoma

Interventions

  • cyclophosphamideDrug

    drug is used in first line treatment in combination (COPP or COPDAC)

  • dacarbazineDrug

    drug is used in first line treatment in combination (COPDAC)

  • prednisoloneDrug

    drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

  • prednisoneDrug

    drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

  • procarbazine hydrochlorideDrug

    drug is used in first line treatment in combination (COPP)

  • vincristine sulfateDrug

    drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

  • fludeoxyglucose F 18Radiation

    used as a diagnostic marker for metabolically active tumour at staging and response assessment

  • radiation therapyRadiation

    part of combination treatment (combined modality between chemo- and radiotherapy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: 5 years

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitaetsklinikum Giessen-Marburg

    Giessen, Germany

  • Royal Hospital for Sick Children

    Edinburgh, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.